China’s Essential Drug List Expected In June
This article was originally published in PharmAsia News
Executive Summary
At a recent national pharmacist conference in Beijing, high-level executives and experts from China's government organizations such as the Ministry of Health, State FDA and National People's Congress Finance and Economy Committee gathered to discuss the healthcare reform. The spotlight was on the long-awaited essential drug list (PharmAsia News, May 2007, 2009), which authorities indicated would likely be out by the end of June. A large reduction in the number of TCM entries was confirmed. Also, healthcare institutions will need to prescribe essential drugs by percentage of revenue rather than by drug types. Relevant supplementary documents will be issued progressively for the list, including implementation opinions and administration regulations. Analysts believe that in the short term, the essential drug market will be concentrated at grassroots-level and rural medical organizations. (Click here for more - Chinese Language)
You may also be interested in...
China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D
SHANGHAI - China's essential drug system will hasten the consolidation of the generic industry while a measure for drug pricing will encourage innovation, according to a Frost & Sullivan report on the impact of China's healthcare reform, released May 18
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.